What is Organoid?

A Complete Guide to In Vitro Bionic “Mini-Organs”
Growing beating mini-hearts, secreting mini-livers, and even functional mini-brains in a Petri dish is not science fiction. It is a biomedical revolution. Today we introduce organoids, named 2017 Method of the Year by Nature Methods.1

Organoids are 3D mini-organs formed by stem cells through in vitro 3D culture. They are not real organs, but highly mimic real human tissues in structure and function.
Unlike traditional 2D cells grown flat on a plate, organoids are 3D structures that spontaneously form complex organ-like architectures.
Technology Milestones

• 2009: Hans Clevers (Netherlands) first established self-renewable mouse intestinal organoids, marking the birth of modern organoid technology.
• 2013: Human intestinal organoids were successfully established; stomach, liver, lung, brain, kidney organoids followed.
• 2017: Named Method of the Year by Nature Methods.
• 2024: Heart, liver, lung, kidney, retina, pancreas and other major organ models are widely available and entering clinical translation. Two Types of Cell Sources 1.Adult Stem Cells (ASCs) Derived from human tissues (intestinal crypts, gastric epithelium).
• Advantages: Preserve original tissue characteristics; ideal for tumor organoids.
• Disadvantages: Limited differentiation potential; requires tissue containing stem cells.

2.Pluripotent Stem Cells (PSCs)
Including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs).

• Advantages: Can differentiate into any cell type; suitable for complex organs such as the brain.
• Disadvantages: High technical difficulty.

Culture Principle
Cells are embedded in extracellular matrix hydrogel (e.g., Matrigel) with specific growth factors (EGF, R-spondin, Noggin, etc.). Cells then self-assemble into organ structures spontaneously.
Four Core Applications
1.Disease Modeling: Patient-derived tumor organoids (PDOs) recapitulate genomic and pathological features, supporting precision medicine.
2.Drug Screening: Serves as a “patient avatar” to predict efficacy and toxicity, reducing R&D costs and failure rates.
3.Regenerative Medicine: Organoid transplantation restores tissue function; future “lab-grown organ patches” may repair damaged organs.
4.Personalized Medicine: Biopsy → culture organoids → drug testing → optimal therapy selection, enabling true personalized treatment.

Technology Frontiers

• Vascularization: Microfluidic technology provides vascular perfusion.
• Immune co-culture: Simulates real tumor immune microenvironment.
• Organ-on-a-chip: Combines organoids with microchips for high-throughput testing.
• Gene editing: Uses CRISPR-Cas9 to construct genetically defined organoids.

Challenges

• Insufficient maturity (most resemble fetal organs)
• Batch-to-batch variation
• Size limitations
• Ethical considerations (especially brain organoids)

Outlook
Organoids will become a core pillar of precision medicine and regenerative medicine, with explosive market growth expected from 2024 to 2029.